Tabituximab Barzuxetan Biosimilar Antibody Conjugate (FZD10) for Research
Pre-made Tabituximab Barzuxetan benchmark antibody (Whole mAb ADC, anti-FZD10 therapeutic antibody, Anti-CD350/FZ-10/Fz10/FzE7/hFz10 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1001-1mg | 1mg | |
| GMP-Bios-INN-1001-10mg | 10mg | |
| GMP-Bios-INN-1001-100mg | 100mg | |
| GMP-Bios-INN-1001-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tabituximab Barzuxetan Biosimilar, Whole Mab Adc, Anti-Fzd10 Antibody: Anti-CD350/FZ-10/Fz10/FzE7/hFz10 therapeutic antibody Drug Conjugate |
| INN Name | Tabituximab Barzuxetan |
| Target | FZD10 |
| Format | Whole mAb ADC |
| Derivation | Chimeric |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | OncoTherapy Science Inc. (Kawasaki Japan) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - FZD10
1. Protein Frizzled-10
2. Gene FZD10
3. Organism Homo sapiens (Human)
Function
Receptor for Wnt proteins. Functions in the canonical Wnt/beta-catenin signaling pathway (By similarity).
The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable).

